Search

Your search keyword '"Steg, Ph. Gabriel"' showing total 586 results

Search Constraints

Start Over You searched for: Author "Steg, Ph. Gabriel" Remove constraint Author: "Steg, Ph. Gabriel" Language english Remove constraint Language: english
586 results on '"Steg, Ph. Gabriel"'

Search Results

2. Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome

7. Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome

8. Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHF

11. Balance of benefit and risk of ticagrelor in patients with diabetes and stable coronary artery disease according to bleeding risk assessment with the CRUSADE score: Data from THEMIS and THEMIS PCI

16. A randomized trial of icosapent ethyl in ambulatory patients with COVID-19

18. Prevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial

19. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

22. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery

23. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

26. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial

28. Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG

29. Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials

30. Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial.

32. Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease

34. Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses

39. Do patients benefit from omega-3 fatty acids?

43. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

45. Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease

47. Time to clinical benefit with sotagliflozin in patients with type 2 diabetes and chronic kidney disease: Insights from the SCORED randomized trial.

49. Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention: Results From CHAMPION PHOENIX

Catalog

Books, media, physical & digital resources